AG Pharma is a theranostics company developing monoclonal-antibody medicines and companion diagnostic tests for cancer-specific targets. Its proprietary biomarker discovery platform links earlier disease detection with more individualized treatment, while its pipeline includes Progranulin, a monoclonal antibody intended for research use in breast cancer and other diseases. The company’s focus is co-developing diagnostic and therapeutic products that help identify responsive patients and monitor treatment.
Facili Bio LLCFacili Bio LLC uses an AI-powered drug-discovery platform and proprietary computational biology to develop new cancer treatments. The company focuses on difficult areas of oncology, pairing research into patient-specific therapies with clinical studies intended to move promising discoveries toward patients.ALBANY, NY
Tavotek BiotherapeuticsTavotek is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. The company leverages proprietary antibody engineering platforms to generate high-affinity, high-specificity antibodies targeting disease-relevant antigens in Oncology and Immunology.LOWER GWYNEDD, PA
NuVue Therapeutics, IncNuVue Therapeutics, Inc. is a medical device, diagnostics, and drug delivery company with an initial focus on accurate diagnosis and targeted treatment of liver, pancreatic, and other hard-to-treat soft-tissue cancers. The company designs diagnostic products to give a bright, clear image of biopsy needles in real-time during procedures and to accurately mark sites for further imaging and/or biopsies. It also designs therapeutic products to avoid the toxic effects of systemic chemotherapy by providing targeted delivery of free and encapsulated drugs and thermal effects directly into tumors.FAIRFAX, VA
Molecular Targeting Technologies, IncPrivately held and clinical-stage, Molecular Targeting Technologies, Inc. is known for advancing radiopharmaceutical research aimed at rare cancers. Its EvaThera platform, licensed worldwide from the National Institutes of Health, supports targeted diagnosis and treatment for patients whose tumors express specific molecular markers.WEST CHESTER, PA